Pill reduced number of multiple sclerosis lesions in Phase II trial

An investigational oral drug called ONO-4641, a sphingosine 1-phosphate receptor modulator, reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase two clinical trial to be presented as Emerging Science (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.